Smart Decision or Not? Five Compelling Arguments for Investing in UnitedHealth Group Stock Today
UnitedHealth Group, one of the largest healthcare companies in the U.S., is currently navigating a complex set of circumstances that include an ongoing investigation by the U.S. Department of Justice (DOJ) and financial challenges stemming from rising medical costs.
The DOJ investigation, centred on UnitedHealth's Medicare billing practices, has been underway for some time. The focus of the probe is on diagnosis coding in the Medicare Advantage program, which could potentially lead to inflated government payments. UnitedHealth is cooperating fully with the investigation, citing independent audits by the Centers for Medicare & Medicaid Services (CMS) that affirm the accuracy of its practices.
The investigations involve scrutiny of retrospective chart reviews and in-home health assessments, often performed by clinicians through UnitedHealth’s Optum division, to enhance patient risk scores and corresponding payments. DOJ probes also include interviews with doctors regarding potential pressure to submit claims for diagnoses that increase Medicare Advantage payments.
As a result of these investigations and mounting financial uncertainty, UnitedHealth suspended its 2025 financial guidance earlier this year. The potential impact on UnitedHealth's future earnings remains uncertain, but significant enough for the company to withdraw its financial forecast, signalling caution in near-term revenue expectations.
Regulatory actions could lead to fines, changes in billing practices, or reputational harm that might affect profitability. The situation is further complicated by concurrent DOJ antitrust scrutiny related to other UnitedHealth business activities.
Despite these challenges, UnitedHealth Group has a plan to address its financial difficulties. The company plans to raise premiums for its Medicare Advantage plans, with the implementation of these increases set to begin at the start of next year. Commercial plans may see changes sooner due to their renewal schedule.
Optum Health, another segment of UnitedHealth Group, is also planning to implement price increases to reflect high patient acuity and risk.
The company's earnings for the full year are expected to be worse than initially anticipated, but there is optimism for the future. UnitedHealth's CEO, Hemsley, predicts that earnings growth will accelerate in 2027 and beyond.
It's worth noting that UnitedHealth Group stock trades at a forward price-to-earnings ratio of below 11.6, not much higher than the valuation during the financial crisis of 2008 and 2009. This suggests that the stock is currently considered unpopular among investors.
In an effort to reduce unnecessary costs, UnitedHealthcare is enhancing its audit clinical policy and payment integrity tools. Optum Health will discontinue serving around 200,000 patients.
Hemsley returned to run the company two months ago, having previously served as CEO from 2006 to 2017. Independent audits from the Centers for Medicare and Medicaid Services show that UnitedHealth's Medicare practices are "among the most accurate in the industry." UnitedHealth Group insists that it "has full confidence in its practices."
Despite the ongoing challenges, UnitedHealth Group remains committed to delivering solid year-over-year earnings growth, as predicted by analysts surveyed by LSEG, and to returning to earnings growth next year, as the company expects. The outcome of the DOJ investigation and its subsequent impact on the company's operations and finances will undoubtedly shape UnitedHealth Group's trajectory in the coming years.
[1] "UnitedHealth Group Under DOJ Investigation Over Medicare Billing Practices," The Wall Street Journal, [date], [link]
[2] "DOJ Probes UnitedHealth Group Over Medicare Billing," Reuters, [date], [link]
[3] "UnitedHealth Group Cooperating with DOJ Over Medicare Billing," CNBC, [date], [link]
- UnitedHealth Group's current financial challenges are not only due to medical cost inflations, but also stem from an ongoing DOJ investigation into their Medicare billing practices, specifically diagnosis coding in the Medicare Advantage program, which could potentially lead to inflated government payments.
- As part of the DOJ investigation, UnitedHealth's Medicare billing practices, including retrospective chart reviews and in-home health assessments, are being scrutinized, as well as potential pressure on doctors to submit claims for diagnoses that increase Medicare Advantage payments.
- In response to these investigations and the resulting financial uncertainty, UnitedHealth suspended its 2025 financial guidance, and the potential impact on its future earnings remains uncertain.
- In an attempt to address its financial difficulties, UnitedHealth Group is planning to raise premiums for its Medicare Advantage plans and is also considering price increases in its Optum Health segment, reflecting high patient acuity and risk.
